DiaMedica TherapeuticsDMAC +1.75%31 PB Ratio is 7.25 as of Jun. 25, 2026, which is 87% above its 10-year median of 3.87. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, DiaMedica Therapeutics ranks worse than 79.81% on this metric.
The historical rank and industry rank for DiaMedica Therapeutics's PB Ratio or its related term are showing as below:
DMAC'
s PB Ratio Range Over the Past 10 Years
Min: 1.16 Med: 3.87 Max: 51.46
Current: 7.25
During the past 13 years, DiaMedica Therapeutics's highest PB Ratio was 51.46. The lowest was 1.16. And the median was 3.87.
DMAC's PB Ratio is ranked worse than 79.81% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs DMAC: 7.25
During the past 12 months, DiaMedica Therapeutics's average Book Value Per Share Growth Rate was 10.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of DiaMedica Therapeutics was 123.10% per year. The lowest was -50.70% per year. And the median was -2.65% per year.
Back to Basics: PB Ratio
DiaMedica Therapeutics (NAS:DMAC) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, DiaMedica Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
DiaMedica Therapeutics (DMAC) has a PB Ratio of 7.25 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DiaMedica Therapeutics and its competitors. This is 87% above median its historical median of 3.87. Over the past decade, DiaMedica Therapeutics' PB Ratio has ranged from 1.16 to 51.46. According to the industry distribution chart, DiaMedica Therapeutics ranks #984 out of 1233 companies in the Biotechnology industry, placing it in the top 79.8%.
Is DiaMedica Therapeutics' PB Ratio too high?
DiaMedica Therapeutics' current PB Ratio of 7.25 is 87% above median its 10-year median of 3.87. Over the past 10 years, this metric has ranged from a low of 1.16 to a high of 51.46. The Biotechnology industry median PB Ratio is 2.83. DiaMedica Therapeutics' value of 7.25 is 156.2% above this industry median. Based on the distribution chart, DiaMedica Therapeutics ranks #984 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' PB Ratio compare to BCYC and RZLT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #984 out of 1233 companies for PB Ratio. This places DiaMedica Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.83. DiaMedica Therapeutics' value of 7.25 is 156.2% above this benchmark. Historically, DiaMedica Therapeutics' own PB Ratio has ranged from 1.16 to 51.46 over the past decade. While the company's 10-year median is 3.87 vs. the industry median of 2.83, DiaMedica Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DiaMedica Therapeutics's current PB Ratio of 7.25 is 156.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DiaMedica Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current PB Ratio is 7.25, which is 87% above median its own 10-year median of 3.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current PB Ratio of 7.25. The current PB Ratio is 7.25, which is 87% above median its 10-year median of 3.87 and 156.2% above the Biotechnology industry median of 2.83. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current PB Ratio is 7.25 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score
Get the complete analysis for DMAC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
